once in Medical Technology

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced positive results from a study comparing subjects randomized to...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-ter...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

Data Findings Published in June Issue of Circulation SILVER SPRING, Md. and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and Eli Lilly and Company (NYSE: LLY ) today announced the results of a pivotal 16-week study showing that a once-dail...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Improvements in Systolic Blood Pressure and Triglycerides Also Observed NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...

Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples

Data Published in May Issue of Journal of Sexual Medicine INDIANAPOLIS, May 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-...

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

Companies Committed to Investing in New Product Presentations for Patients SAN DIEGO and INDIANAPOLIS, April 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced that the companies have agreed in principle to the ...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced positive results from DURATION-2, the second in a series of studies designed to...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 11 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced that the U.S. Food and Drug Administration (FDA) recently indicated that the ongoing ext...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (N...

Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight

DURATION-1 Data Presented at the 68th Annual Scientific Sessions of the American Diabetes Association SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) anno...

Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis

BRIDGEWATER, N.J. and CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were published this month in the January issue of the peer- reviewe...

Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies

Data Presented at the 2nd Annual International Workshop on Hepatitis C Resistance & New Compounds WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors with potent antiviral activity...

Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks

- MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels with less frequent dosing - NUTLEY, N.J., Oct. 19 /PRNewswire/ -- A pivotal study published today in The Lancet has shown that dialysis patients were effectively switched from frequently-dosed anemia...

New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis

HONOLULU, Sept. 19 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone and Mineral Research (ASBMR) 29th Annual M...

New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures

Data Presented at the American Academy of Neurology Annual Meeting Show Approximately 50 Percent Reduction in Partial Seizures BOSTON, May 01, 2007 /PRNewswire/ -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once ...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...e Vision Center, it is expensive and puts a great strain on the family, especially if they are from another state. Our preliminary research shows that once the cup is fitted, the child should be able go home for several weeks. Because the drug is being administered directly into the eye and not systemical...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...ectal cancer to determine E fficacy) enrolled 1,183 patients globally. Patients were randomized to receive either 6.0 mg/kg of Vectibix and FOLFOX4 once every two weeks (Q2W) or FOLFOX4 alone Q2W. The primary endpoint of the study is progression-free survival by KRAS status and secondary endpoints in...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...n-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide deve...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...d vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OP...

Online H1N1 Management: FairChoice Helps Schools Respond to Infectious Disease on Campus

...ov/h1n1flu/college-alert.htm ). FairChoice Health will also allow campus health officers to manage the administration of an H1N1 vaccine to students once it is available. FairChoice Health is based on technology developed and in use at Columbia University for compliance with New York State Public...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...om these first three cohorts demonstrate that we have achieved our goal of identifying a nucleotide analog with good efficacy that can be administered once daily at a low milligram dose. Given these characteristics and the potential benefits of nucleotide analogs over other classes of HCV direct acting an...

New Powder Speeds Healing of Difficult Foot Wounds

...of Podiatric Medicine. The study focused on atypical wounds with irregular shapes and causes. The wounds were treated with the powder dressing once a week for four to eight weeks. The study ultimately showed that the powder dressing provided a painless, efficient, and protective treatment that as...

Is Your Hair Taking a Break?

...," said Dr. McMichael. "In these cases, I would only recommend minoxidil to less than 50 percent of women and oral medications would not be effective. once the trigger is removed, the hair simply needs to return to normal -- which could take anywhere from three to nine months. The key is determining the t...

Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin

... experience thicker hair and glowing skin. On the other hand, post-menopausal women may notice that their skin does not have the same elasticity as it once did and that it is drier than normal. In order to treat the most common symptoms associated with menopause -- including hot flashes, mood swing...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

... Giese, President and CEO of BioMS Medical. "We are fortunate to have suitable resources in place to remain flexible to pursue whatever options emerge once we understand these results more fully." BioMS Medical Webcast Participants may listen to a discussion of the outcome of the MAESTRO-01 ...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

... in 1957 which revolutionized the way women cared for their skin by providing the first alternative to soap that was less drying to skin. Now, Dove is once again bringing category-changing technology to the personal wash category. "For over fifty years, Dove has led innovations in the skin care ind...

Injection Reverses Heart-Attack Damage

...ng pediatric cardiologist at Children's since 2007. When the team injected NRG1 into the peritoneal cavity of live mice after a heart attack, once daily for 12 weeks, heart regeneration was increased and pumping function (ejection fraction, assessed on echocardiograms) improved as compared with u...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

... development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide deve...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

...drome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations. In addition to LX1032, Lexicon ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

... development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide deve...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...ial trial (n=2762). Patients were randomized to receive various combinations of Tekturna (75 mg to 300 mg) plus hydrochlorothiazide (6.25 mg to 25 mg) once daily (without titrating up from monotherapy) and followed for blood pressure response. The combination of Tekturna and hydrochlorothiazide resulted i...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

...rmeability of B. cepacia's cell envelope. In addition, B. cepacia - just like many other pathogens - has developed mechanisms to eliminate antibiotics once they have entered the cell. Fluidosomes(TM)-tobramycin seems to overcome these limitations by packing tobramycin into liposomes, which, by allowing ef...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of ...retroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown to have a more favorable lipid safety prof...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

...lvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than ...ot reach as high as when the compound is delivered once per day. "When we assessed the pharmacokinetics in patients taking edoxaban once a day, lower minimum concentrations and fewer blee...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

...CorMatrix ECM is derived from porcine small intestines and is processed in a way that removes all cells, leaving the complex structural matrix intact. once surgically implanted, it serves as a scaffold, allowing the patient's cells to infiltrate and ultimately replace the ECM scaffold. While the pat...

Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy

...an, Director, Stem Cell Research and Regenerative Medicine, Columbia University Medical Center, discussed the anticipated MARVEL study, "this study, once completed, will be the bench mark and we are all very optimistic. Thomas Povsic, Assistant Professor of Medicine, Duke University Medical Center wo...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

...year open-label study was specifically designed to further characterize the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 patients; NPH twice daily: 509 patients). Retinopathy progression was assessed using serial fundus photography. Progression was evalu...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

...olent disease characteristics." Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to pub...

Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.

...of infestations the gallon size is nearly always sufficient for an entire year for most homes. For those concerned with the smell, the odor disappears once the garlic extract diluted in water dries, typically within 3 to 4 hours. Mosquito Barrier is currently being used successfully in a wide variety...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

... an evaluation of the efficacy and safety of NUVIGIL (50 or 150 mg/day) in 427 healthy men and women who all had experienced jet lag symptoms at least once during the previous five years. Clinical efficacy was evaluated using two primary endpoints: an objective assessment -- the Multiple Sleep Latency Te...